Stock SLNCF SILENCE THERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Silence Therapeutics plc OTC Markets

Equities

SLNCF

GB00B9GTXM62

Market Closed - OTC Markets
Other stock markets
 17:02:30 26/06/2024 BST 		5-day change 1st Jan Change
6.5 USD -.--% Intraday chart for Silence Therapeutics plc -.--% +333.33%
06-28 European Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading MT
06-28 Chardan Raises Price Target on Silence Therapeutics to $55 From $42, Maintains Buy Rating MT

Evolution of the average Target Price on Silence Therapeutics plc

Price target over the last 5 years

History of analyst recommendation changes

baec278a3350e42c5f2a8af7ea9a.Oz2Sr1YkrAh21Co9XbXgM6K7j3YfU4ptKvFCxOcSmNA.DAvmxGdXmzkYmmN8Etmodubi5TV3KecEWqkas5Erx4pPCKGaG1DGcQeHew~14d60471231919b2f250fc29eff5398c

Analyst Recommendations on Silence Therapeutics plc

Chardan Raises Price Target on Silence Therapeutics to $55 From $42, Maintains Buy Rating MT
Morgan Stanley Raises Price Target on Silence Therapeutics to $49 From $45, Keeps Overweight Rating MT
Chardan Boosts Price Target on Silence Therapeutics to $42 From $26 on Positive Data From Zerlasiran Study, Keeps Buy Rating MT
Morgan Stanley Boosts Price Target on Silence Therapeutics to $45 From $29, Says Q4 Showed 'Meaningful Progress,' Keeps Overweight Rating MT
BMO Capital Starts Silence Therapeutics With Outperform Rating, $67 Price Target MT
HC Wainwright Adjusts Silence Therapeutics Price Target to $75 From $80, Maintains Buy Rating MT
Chardan Adjusts Price Target on Silence Therapeutics to $26 From $29, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
19 USD
Average target price
59.2 USD
Spread / Average Target
+211.58%
High Price Target
75 USD
Spread / Highest target
+294.74%
Low Price Target
49 USD
Spread / Lowest Target
+157.89%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Silence Therapeutics plc

Chardan Research
Morgan Stanley
BMO Capital
HC Wainwright

Ratings for Silence Therapeutics plc

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. SLN Stock
  4. SLNCF Stock
  5. Consensus Silence Therapeutics plc